George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I think the worry is (at least with me) that it will fail and fall away into almost nothing.
Where is the revenue coming from to support its activities?
Why the silence on AZ when everyone must be assuming the deal is dead?
etc etc
so take what you can when you can
Hawkander Really????? you sold at 5y low..... you may have been desperate for money then.
I must admit that after I don`t know how many years, I sold my remaining shares, may return at some later date. GLA
This is very unpleasant to watch. Nothing from the company to even attempt to turn it around. Mind you statements don't always do any good as the CEO of Angle just proved managing to knock off all the gains from being FDA approved and then some by saying there is no short term income and he doesn't want short-term investors. Down from 158 to about 103. Even more ouch.
"Can lead" or does lead? "Can lead" is newspaper headline stuff. How much of an increased risk? A relative risk or an absolute risk? Would be good to know.
The AstraZeneca coronavirus vaccine may lead to an increased risk of developing the serious neurological condition Guillain-Barré Syndrome (GBS), which can lead to the rare and terrifying "locked-in" syndrome.
This is one of those shares that will perform over the long term remember the markets are down and may go lower but good companies like Oxford will come through . Now’s the time to think long term holds rather than short term gains . Be patient. Oxford nano, gsk , Abcam, AstraZeneca is a bit high for my liking. Don’t get despondent market is in bear territory but will turn when ? Not soon . but maybe look at bank shares now . Good luck guys.
Well done on Angle. Looks like Oxb is set to depart the ftse 250 next month. Should be built into the sp as it is no surprise now.
I wish I had sold instead of buying. Will hang on and see what happens but I agree that if the AZ deal was ongoing they would have announced it by now.
Have a reasonable amount in Aviva but just did well in Angle today which announced FDA approval for its system - up 55% atm - and should climb higher as income rolls in. You win some and you lose some!
Hi Kern,
Can’t help watching this even though I’m out. Still no news on the Astra vaccine contract so I presume it is dead in the water. The lack of any new contracts can’t be helping either. As for Aviva it is my largest holding by far now so hoping for a decent return.
What has caused this latest fall? I cannot find any new information and now we are solidly below £5.
Shatter; I see you are in AV as well. At least that is doing ok.
I would not expect too much from an CEO who said recently(April 2022)
"I am delighted with our performance in 2021 which was a true testament to the hard work of all our employees," said chair and interim chief executive officer Dr Roch Doliveux.
He must be blind not to see the share price which is indicative of the company's performance.
Assume their is no imminent news otherwise directors would not have been able to buy. However they may know of things in the pipeline that will come to fruition in due course.
Director buys should perhaps have been renamed desperation buys - the feeling that you have when you are in such a bad situation that you are willing to take risks in order to change it:
Well… the director buys have really worked ! As for directors selling major holdings that would be the kiss of death so they are hurting like everyone else. Other posters are hoping , if not praying, for a buyout at this lowly price. Need a contract or two to stop the rot.
I hope so. In answer to P no I am not paid to make things up. I first invested in OXB in July 2004 and have been a shareholder ever since adding here and there; sometimes at the wrong time so I now have an average of £7.24 which I hope helps explain my concern about this precipitous fall and the lack of communication from the company and my search for possible explanations.
GLALTH
Yes but there have been other director purchases recently at market prices and also Slingsby continues to hold a significant number of shares. He's not compelled to keep all the free shares he gets. Hardly rats leaving a sinking ship. Maybe they know something we don't.
I do read things and it is hard to see how this is a buy
Oxford, UK - 03 May 2022: Oxford Biomedica plc ("Oxford Biomedica" or "the Company") (LSE: OXB), was informed on 03 May 2022, that Dr. Jason Slingsby, Chief Business & Corporate Development Officer of the Group, exercised 8,712 LTIP (2018) options at nil cost on 27 April 2022, and sold all the resulting ordinary shares at 539.0p per share. Following this transaction Dr. Jason Slingsby continues to hold 120,476 options over ordinary shares.
@kernowlad Do you actually read anything before you post or you are paid to make things up, the management bought shares not dumped them and some institutions increased their positions
I am always amazed how some posters mislead the boards
Hi Kern,
Yeah, it doesn’t look very temporary, unfortunately.
Doesn't look temporary. Hard to see what will reverse this decline. Market has lost faith/patience with OXB according to the sp. The heady £15 days may be over for good so its about minimising losses now - after 20 years!
Let’s hope it’s only temporary. Oxb are going to need a miracle to stop this decline ! The vaccine contract has got to be finished whether Oxb want to admit it or not.
As usual Oxb is short on detail -The Company has fully drawn down the $85m Short Term Loan Facility with Oaktree which has been used to temporarily bridge fund the Acquisition and the $50m cash injection into Oxford Biomedica Solutions. Millions in interest on this very expensive loan/ debt. No mention of cash burn and how long before the coffers are empty ! Judging by the sp the market is not impressed .
Depending on the cash burn but yes atm they would appear to be ok. I misread the figures but with limited income and the US company seemingly making losses how long will the current cash last.
What debt? At 31 December OXB had £109m of cash and has since raised a further £80m. So, despite the US investment of c£134m, that would still leave OXB with c£55m of cash.
It's never a good sign when senior staff quickly want to dump stock and the sp has reacted accordingly.
I don't think I will average down as it has the feeling of throwing good money after bad.
Could OXB actually go under with its debt and losses without the vaccine?